Nivolumab is a human IgG4 monoclonal antibody that targets the PD-1 receptor on T-cells, disrupting its interaction with PD-L1 and PD-L2. This releases the immune inhibition mediated by the PD-1 pathway, enabling T-cells to recognize and destroy cancer cells. When combined with ipilimumab (a CTLA-4 inhibitor), it enhances T-cell activation, promoting a more potent anti-tumor response.
১০০% অরিজিনাল পণ্যের নিশ্চয়তা
Safe & Secure Payments, Always
Fast, Secure & Efficient Delivery
Proper Packaging
Navigo 40 (Nivolumab) is a PD-1 immune checkpoint inhibitor indicated for the treatment of various cancers, including:
ওয়েবসাইট থেকে অর্ডার করার সহজ ভিডিও গাইড।
অ্যাপ থেকে অর্ডারের সহজ ভিডিও গাইড
অ্যাপ ডাউনলোডePharma অ্যাপ ডাউনলোড বিস্তারিত গাইড ›অ্যাপে অর্ডারের বিস্তারিত গাইডNivolumab is administered via intravenous infusion. The dosage and schedule vary by indication and may be used alone or in combination with ipilimumab, chemotherapy, or targeted therapy. Common regimens include:
Infusions are given over 30 minutes using a sterile, low protein-binding filter.
Preparation
Dilute with 0.9% Sodium Chloride or 5% Dextrose to a final concentration of 1–10 mg/mL. Do not exceed 160 mL total infusion volume (or 4 mL/kg in patients under 40 kg). Mix gently—do not shake. Administer within 8 hours at room temperature or store up to 7 days at 2–8°C protected from light.
- Pediatric: Not established in patients under 12 years (mCRC) or under 18 for other uses.
- Geriatric: No significant differences in safety or efficacy compared to younger patients.
Keep refrigerated at 2°C to 8°C. Do not freeze. Protect from light and keep out of children's reach.
⚠️Disclaimer:
At ePharma, we’re committed to providing accurate and accessible health information. However, all content is intended for informational purposes only and should not replace medical advice from a qualified physician. Please consult your healthcare provider for personalized guidance. We aim to support, not substitute, the doctor-patient relationship.